Acceptance Factors of Pneumococcal Vaccination Among Adult Population: A Systematic Review

Siti Nor Mat, Norzaher Ismail, Syafiq Taib, Hasanain Faisal Ghazi, Zahir Izuan Azhar, Mohammad Saffree Jeffree, Azmawati Mohammed Nawi, Mohd Rohaizat Hassan


Introduction : Pneumococcal disease causes considerable morbidity and mortality, including among adults. Adult pneumococcal vaccines help to prevent these burdens, yet, they are underutilized. Our objective is to systematically collect and summarize the available evidence on the potential factors that lead to pneumococcal vaccination acceptance among of adult community.

Methodology: A systematic literature search was conducted involving studies published from January 1999 to December 2015. The studies were identified by searching electronic resources (PubMed/MEDLINE and Pro Quest database) and manual searches of references. Study setting was focused on factors and determinants that associated with pneumococcal vaccination intake or acceptance. Final studies result and data were reviewed by two independent authors. Disagreement was resolved through discussion and consensus.

Results: 17 studies were included in final discussion with 10 domains identified in the paper. 7 studies (41%) reported that the provider domain, patients’ perception and socio-demographic factor had the most effect on the pneumococcal vaccination acceptance rate. In addition, only 18% (3) of reviewed papers highlighted that socio-economic factor influenced the pneumococcal vaccination acceptance while 24% (4 studies) were attributed to the comorbid domains.

Conclusion:  Healthcare provider and patients’ perception about pneumococcal vaccination for adult population are significant domains that influence the acceptance towards vaccination. Strong recommendations from healthcare provider for pneumococcal vaccination would be an important step to increase vaccination acceptance among the population


Pneumococcal vaccination, adult population, acceptance.

Full Text:



File TM. Community-acquired pneumonia. Lancet. 2003;362(9400):1991–2001

Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3).

World Health Organization. Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. WER 2007;82(12): 93–104.

Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bulletin of the World Health Organization. 2008;86(5):408-16. doi: 10.2471/BLT.07.048769. PubMed PMID: PMC2647437

O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374(12):893–902.

Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179–86.

Centres for Disease Control and Prevention. Recommended adult immunization schedule- United States, MMWR. 2009;57(53): Q1–Q4.

Centres for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61:816-19.

Centres for Disease Control and Prevention. Progress in introduction of pneumococcal conjugate vaccine – worldwide, 2000–2008 [online]; 2008 [cited 01.02.12]. Available from: HYPERLINK mmwr/preview/mmwrhtml/mm5742a2.htm

United States Department of Health and Human Services. Healthy People 2010. With Understanding and Improving Health and Objectives for Improving Health, 2 Vols., 2nd edn. Washington, DC: U.S. Department of Health and Human Services; 2000.

Kellner JD. Update on the success of the pneumococcal conjugate vaccine. Can Paediatr Soc 2011;16(April (4)):233–40.

Centres for Disease Control and Prevention. 2008. Available from: Accessed October 2, 2017.

Metersky ML, Mennone JZ, Fine JM. Factors inhibiting use of the pneumococcal polysaccharide vaccine: A survey of Connecticut physicians. Conn Med 1998; 62: 649–654.

Centres for the Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997; 46(RR-8):1–24.

Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med. 2006; 31: 72–9. [PubMed: 16777545].

Shevlin JD, Summers-Bean C, Thomas D, Whitney CG, Todd D, Ray SM. A systematic approach for increasing pneumococcal vaccination at an inner-city public hospital. Am J Prev Med. 2002; 22: 92–7.

Hak E, Grobbee DE, van Essen GA, et al. Pneumococcal vaccination in the elderly: do we need another trial? Arch Intern Med. 2000; 160:1698–1699.

Clutterbuck EA, Lazarus R,Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis2012; 205: 1408-16.

Bovier PA, Chamot E, Gallacchi MB, Loutan L. Importance of patients’ perceptions and general practitioners’ recommendations in understandingmissed opportunities for immunization in Swiss adults. Vaccine. 2001; 19:4760–7.

Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T. Pneumococcal vaccination: what have we learnt so far and what can we expect in the future? European Journal of Clinical Microbiology & Infectious Diseases. 2015;34(1):19-31

Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ : Canadian Medical Association Journal. 2009;180(1):48-58.

Kellner JD. Update on the success of the pneumococcal conjugate vaccine. Paediatrics & Child Health. 2011;16(4):233-6

Wahid ST, Nag S, Bilous RW, Marshall SM, Robinson AC. Audit of influenza and pneumococcal vaccination uptake in diabetic patients attending secondary care in the Northern Region. Diabetic medicine : a journal of the British Diabetic Association. 2001;18(7):599-603

Kyaw MH, Nguyen-Van-Tam JS, Pearson JC. Family doctor advice is the main determinant of pneumococcal vaccine uptake. Journal of Epidemiology and Community Health. 1999;53(9):589-90

Opstelten W, Hak E, Verheij TJM, van Essen GA. Introducing a pneumococcal vaccine to an existing influenza immunization program: vaccination rates and predictors of noncompliance. The American Journal of Medicine. 2001;111(6):474-9

Nowalk MP, Zimmerman RK, Tabbarah M, Raymund M, Jewell IK. Determinants of adult vaccination at inner-city health centers: A descriptive study. BMC Family Practice. 2006;7:2

Ridda I, Motbey C, Lam L, Lindley IR, McIntyre PB, Macintyre CR. Factors associated with pneumococcal immunisation among hospitalised elderly persons: a survey of patient's perception, attitude, and knowledge. Vaccine. 2008;26(2):234-40.

Egede LE, Zheng D. Racial/Ethnic Differences in Adult Vaccination Among Individuals With Diabetes. American Journal of Public Health. 2003;93(2):324-9.

Loubet P, Kerneis S, Groh M, Loulergue P, Blanche P, Verger P, et al. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine. 2015;33(31):3703-8.


  • There are currently no refbacks.

Copyright (c) 2018 Siti Nor Mat, Norzaher Ismail, Syafiq Taib, Hasanain Faisal Ghazi, Zahir Izuan Azhar, Mohammad Saffree Jeffree, Mohd Rohaizat Hassan

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.